Zenosense
is focused on emerging technology. From the start, the healthcare technology
company has sought to develop an operational Super-Bug or Methicillin-resistant
Staphylococcus aureus (MRSA) detector for use in hospitals, clinical
environments and other healthcare settings.
Last year,
Zenosense outsourced the development of its device to The Sgenia Group, a
well-known sensor developer. Sgenia intends to model the new device after the
algal (water) sensor platform it developed and to use a solo, commercial
“off-the-shelf” gas sensor to sample the air and continuously check for the
airborne Volatile Organic Compounds signature emitted by MRSA/SA. The device
development process is intended to be completed in three distinct phases:
• Phase 1
The first
phase will be to produce a prototype that leverages Sgenia’s technology and
successfully detects MRSA/SA contamination. Significant engineering work will
be needed to adjust and adapt existing sensor capabilities to the planned
application. The modification of algorithms will also be required to conform to
MRSA/SA bacteria analysis. All of these developments will most likely be
protected as industrial secrets rather than patents.
• Phase 2
The second
phase will be to build prototypes as well as conduct lab tests with a minimum
of 20 beta versions of the MRSA/SA detection device. Next, a pre-production
design appropriate for hospital use will have to be delivered. A vital aspect
of this phase will be authenticating the device and achieving accuracy and
repeatability. Testing will include: addressing the contaminating influences of
environmental conditions, like humidity, temperature and other gasses, as well
as the interference from other families of bacteria; and achieving the standard
and quality levels required for hospital use.
• Phase 3
The third
and final phase will be to obtain pertinent regulatory approvals in the United
States and European Union and to produce a final product ready for mass
production and marketing. Steps during this phase will include: final testing
by an external and specialist laboratory of microbiology; preparing and
pursuing applications for approval; remedying any problems detected during
testing; as well as preparing for mass production of the device, once all
relevant tests and approvals are obtained.
The
development of the Zenosense device started in December 2013. Months later, in
late October 2014, Zenosense announced that major progress had been made in the
development of its MRSA/SA detector. The prototype device successfully achieved
a sensibility detection rate greater than 95% on cultured headspace in a
sequence of tests over a two-week period in a clinical setting. The general
development of the device technology, which will detect the MRSA Super-Bug, was
also proceeding in line with the company’s expectations.
For more
information, visit www.zenosense.net
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see
disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment